Epsilon Healthcare Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Epsilon Healthcare's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 16.1% per year.
Anahtar bilgiler
-4.2%
Kazanç büyüme oranı
9.1%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 31.2% |
Gelir büyüme oranı | 16.1% |
Özkaynak getirisi | -64.7% |
Net Marj | -82.2% |
Son Kazanç Güncellemesi | 30 Jun 2023 |
Yakın geçmiş performans güncellemeleri
Recent updates
Does Epsilon Healthcare (ASX:EPN) Have A Healthy Balance Sheet?
Oct 13Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?
Jun 30We Think Epsilon Healthcare (ASX:EPN) Has A Fair Chunk Of Debt
Sep 26Is Epsilon Healthcare (ASX:EPN) Weighed On By Its Debt Load?
Jun 13Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?
Feb 27Gelir ve Gider Dağılımı
Epsilon Healthcare nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 23 | 7 | -6 | 5 | 0 |
31 Mar 23 | 7 | -10 | 6 | 0 |
31 Dec 22 | 7 | -13 | 6 | 0 |
30 Sep 22 | 6 | -13 | 7 | 0 |
30 Jun 22 | 5 | -13 | 7 | 0 |
31 Mar 22 | 5 | -11 | 8 | 0 |
31 Dec 21 | 5 | -9 | 10 | 0 |
30 Sep 21 | 6 | -9 | 11 | 0 |
30 Jun 21 | 7 | -9 | 12 | 0 |
31 Mar 21 | 7 | -10 | 11 | 0 |
31 Dec 20 | 7 | -11 | 11 | 0 |
30 Sep 20 | 7 | -11 | 11 | 0 |
30 Jun 20 | 6 | -12 | 11 | 0 |
31 Mar 20 | 5 | -12 | 10 | 0 |
31 Dec 19 | 5 | -12 | 10 | 0 |
30 Sep 19 | 4 | -11 | 9 | 0 |
30 Jun 19 | 4 | -11 | 9 | 0 |
31 Mar 19 | 3 | -10 | 9 | 0 |
31 Dec 18 | 3 | -9 | 8 | 0 |
30 Sep 18 | 3 | -7 | 7 | 0 |
30 Jun 18 | 3 | -5 | 6 | 0 |
31 Mar 18 | 2 | -4 | 5 | 0 |
31 Dec 17 | 2 | -3 | 3 | 0 |
Kaliteli Kazançlar: EPN is currently unprofitable.
Büyüyen Kar Marjı: EPN is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: EPN is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.
Büyüme Hızlandırma: Unable to compare EPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: EPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Özkaynak Getirisi
Yüksek ROE: EPN has a negative Return on Equity (-64.69%), as it is currently unprofitable.